Literature DB >> 34609930

Cost-effectiveness of consolidation durvalumab after chemo-radiotherapy in stage III non-small-cell lung cancer: A cost-effective change.

Jacopo Giuliani1, Maurizio Valentino Infante2, Claudio Micheletto3, Andrea Bonetti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34609930     DOI： 10.1177/10781552211045362

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN： 1078-1552            Impact factor:   1.809


× No keyword cloud information.
  1 in total

1.  Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancer.

Authors:  Alessandra Buja; Giulia Pasello; Marco Schiavon; Giuseppe De Luca; Michele Rivera; Claudia Cozzolino; Anna De Polo; Manuela Scioni; Alberto Bortolami; Vincenzo Baldo; PierFranco Conte
Journal:  Thorac Cancer       Date:  2022-08-15       Impact factor: 3.223
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.